Jong‐Mu Sun

Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study

Jong‐Mu Sun, Lin Shen, Manish A. Shah et al. · The Lancet · 2021 · 1.6K citations · Full text

Medicine, Oncology, Pharmacology +14

DNA methylation loss promotes immune evasion of tumours with high mutation and copy number load

Hyunchul Jung, Hong Sook Kim, Jeong Yeon Kim et al. · Nature Communications · 2019 · 563 citations · Full text

Medicine, Immunology, Oncology +17

Tislelizumab Versus Chemotherapy as Second-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma (RATIONALE-302): A Randomized Phase III Study

Lin Shen, Ken Kato, Sung‐Bae Kim et al. · Journal of Clinical Oncology · 2022 · 306 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Pembrolizumab for the treatment of non-small cell lung cancer

Sung Hee Lim, Jong‐Mu Sun, Se‐Hoon Lee et al. · Expert Opinion on Biological Therapy · 2016 · 289 citations

Medicine, Oncology, Pharmacotherapy +17

Artificial Intelligence–Powered Spatial Analysis of Tumor-Infiltrating Lymphocytes as Complementary Biomarker for Immune Checkpoint Inhibition in Non–Small-Cell Lung Cancer

Sehhoon Park, Chan‐Young Ock, Hyojin Kim et al. · Journal of Clinical Oncology · 2022 · 282 citations · Full text

Medicine, Immunology, Oncology +17